These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34532467)

  • 21. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
    McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
    Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive Molecular Characterizations of Chinese Patients With Different Subtypes of Lung Squamous Cell Carcinoma.
    Qian J; Chen R; Zhao R; Han Y; Yu Y
    Front Oncol; 2020; 10():607130. PubMed ID: 33363036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
    Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
    Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-mutation of TP53 and TTN is Correlated with the Efficacy of Immunotherapy in Lung Squamous Cell Carcinoma.
    Ying K; Zou L; Wang D; Wang R; Qian J
    Comb Chem High Throughput Screen; 2023 Oct; ():. PubMed ID: 37904553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor mutation burden (TMB)-associated signature constructed to predict survival of lung squamous cell carcinoma patients.
    Yan D; Chen Y
    Sci Rep; 2021 Apr; 11(1):9020. PubMed ID: 33907270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.
    Jiao XD; Qin BD; You P; Cai J; Zang YS
    Lung Cancer; 2018 Sep; 123():70-75. PubMed ID: 30089598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cdkn2a suppresses metastasis in squamous cell carcinomas induced by the gain-of-function mutant p53(R172H).
    Li Z; Gonzalez CL; Wang B; Zhang Y; Mejia O; Katsonis P; Lichtarge O; Myers JN; El-Naggar AK; Caulin C
    J Pathol; 2016 Oct; 240(2):224-34. PubMed ID: 27447534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer.
    Molina-Vila MA; Bertran-Alamillo J; Gascó A; Mayo-de-las-Casas C; Sánchez-Ronco M; Pujantell-Pastor L; Bonanno L; Favaretto AG; Cardona AF; Vergnenègre A; Majem M; Massuti B; Morán T; Carcereny E; Viteri S; Rosell R
    Clin Cancer Res; 2014 Sep; 20(17):4647-59. PubMed ID: 24696321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of CYP1A1 MSPI polymorphism on the relationship between TP53 mutation and CDKN2A hypermethylation in non-small cell lung cancer.
    Tan C; Xu HY; Zhang CY; Zhang H; Chen CM; Zhang WM; Sun XY; Jin YT
    Arch Med Res; 2011 Nov; 42(8):669-76. PubMed ID: 22154617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival.
    Freudenstein D; Litchfield C; Caramia F; Wright G; Solomon BJ; Ball D; Keam SP; Neeson P; Haupt Y; Haupt S
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CDKN2A(p16) and HRAS are frequently mutated in vulvar squamous cell carcinoma.
    Trietsch MD; Spaans VM; ter Haar NT; Osse EM; Peters AA; Gaarenstroom KN; Fleuren GJ
    Gynecol Oncol; 2014 Oct; 135(1):149-55. PubMed ID: 25072932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutations in the
    Zou S; Ye J; Hu S; Wei Y; Xu J
    Int J Gen Med; 2022; 15():19-31. PubMed ID: 35018111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutational Status of CDKN2A and TP53 Genes in Laryngeal Squamous Cell Carcinoma.
    Todorova TA; Jordanov SH; Stancheva GS; Chalakov IJ; Melnicharov MB; Kunev KV; Mitev VI; Kaneva RP; Goranova TE
    Pathol Oncol Res; 2015 Apr; 21(2):413-21. PubMed ID: 25149524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
    Wang F; Zhao N; Gao G; Deng HB; Wang ZH; Deng LL; Yang Y; Lu C
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):2851-2859. PubMed ID: 32743759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.
    Kron A; Alidousty C; Scheffler M; Merkelbach-Bruse S; Seidel D; Riedel R; Ihle MA; Michels S; Nogova L; Fassunke J; Heydt C; Kron F; Ueckeroth F; Serke M; Krüger S; Grohe C; Koschel D; Benedikter J; Kaminsky B; Schaaf B; Braess J; Sebastian M; Kambartel KO; Thomas R; Zander T; Schultheis AM; Büttner R; Wolf J
    Ann Oncol; 2018 Oct; 29(10):2068-2075. PubMed ID: 30165392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coexistence of YWHAZ amplification predicts better prognosis in muscle-invasive bladder cancer with CDKN2A or TP53 loss.
    Liu S; Wu Y; Yang T; Feng C; Jiang H
    Oncotarget; 2016 Jun; 7(23):34752-8. PubMed ID: 27167196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.
    Tomasini P; Mascaux C; Jao K; Labbe C; Kamel-Reid S; Stockley T; Hwang DM; Leighl NB; Liu G; Bradbury PA; Pintilie M; Tsao MS; Shepherd FA
    Clin Lung Cancer; 2019 May; 20(3):e338-e345. PubMed ID: 30770327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
    Kim A; Lim SM; Kim JH; Seo JS
    Front Immunol; 2021; 12():598671. PubMed ID: 33717076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.